SCHEMBL11909419

SCHEMBL11909419

Nc1ncnc2c1nc(Sc1cc3c(cc1-c1cc[nH]n1)OCO3)n2CCNCCC(=O)NO

nearest known ligand 0.74

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 18/20 0.74
HSP90AB1 P08238 18/20 0.74
HDAC3 O15379 4/20 0.65
HDAC4 P56524 4/20 0.65
HDAC1 Q13547 4/20 0.65
HDAC7 Q8WUI4 4/20 0.65
HDAC2 Q92769 4/20 0.65
HDAC10 Q969S8 4/20 0.65
HDAC11 Q96DB2 4/20 0.65
HDAC8 Q9BY41 4/20 0.65
HDAC6 Q9UBN7 4/20 0.65
HDAC9 Q9UKV0 4/20 0.65
HDAC5 Q9UQL6 4/20 0.65
ERBB2 P04626 3/20 0.48
HSP90B1 P14625 1/20 0.47
TRAP1 Q12931 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11909019 0.96 HSP90AA1 (0.67) HSP90AA1HSP90AB1HDAC3HDAC4HDAC1
SCHEMBL15624901 0.88 HSP90AA1 (0.56) HSP90AA1HSP90AB1HDAC3HDAC4HDAC1
SCHEMBL15624961 0.88 HSP90AA1 (0.56) HSP90AA1HSP90AB1HDAC3HDAC4HDAC1
SCHEMBL1672476 0.88 HSP90AA1 (0.56) HSP90AA1HSP90AB1HDAC3HDAC4HDAC1
SCHEMBL13194029 0.87 HSP90AA1 (0.56) HSP90AA1HSP90AB1HDAC3HDAC4HDAC1
SCHEMBL18203476 0.87 HSP90AA1 (0.80) HSP90AA1HSP90AB1HDAC3HDAC4HDAC1
SCHEMBL15609954 0.87 HSP90AA1 (0.56) HSP90AA1HSP90AB1HDAC3HDAC4HDAC1
SCHEMBL15610356 0.87 HSP90AA1 (0.55) HSP90AA1HSP90AB1HDAC3HDAC4HDAC1
SCHEMBL15624945 0.87 HSP90AA1 (0.56) HSP90AA1HSP90AB1HDAC3HDAC4HDAC1
SCHEMBL15609826 0.87 HSP90AA1 (0.55) HSP90AA1HSP90AB1HDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10172863-B2 Purine derivatives useful as HSP90 inhibitors SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2019-01-08 US claimed
EP-3091019-A2 PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS Sloan Kettering Institute For Cancer Research (US) 2016-11-09 EP claimed
EP-2486039-B1 PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS SLOAN KETTERING INST CANCER (US) 2016-06-01 EP claimed
US-9328114-B2 Hsp90 inhibitors SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2016-05-03 US claimed
US-20120208806-A1 Hsp90 Inhibitors SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2012-08-16 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10172863-B2 Purine derivatives useful as HSP90 inhibitors XDH, HSP90B1, HSP90AA1 HSP90AA1 3/4885HSP90AB1 4/4885HDAC3 2902/4885
US-20120208806-A1 Hsp90 Inhibitors HSP90B1, HSP90AB1, HSP90AB2P HSP90AA1 4/4885HSP90AB1 2/4885HDAC3 1153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.